Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space

Por Sartor, A Oliver
Publicado em 2011

Germline BLM mutations and metastatic prostate cancer

Por Ledet, Elisa M., Antonarakis, Emmanuel S., Isaacs, William B., Lotan, Tamara L., Pritchard, Colin, Sartor, A. Oliver
Publicado no Prostate (2019)

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease

Por Bennett, Charles L., Qureshi, Zaina P., Sartor, A. Oliver, Norris, LeAnn B., Murday, Alanna, Xirasagar, Sudha, Thomsen, Henrik S.
Publicado em 2012

Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer

Por Moses, Marcus, Koksal, Ulkuhan, Ledet, Elisa, Manogue, Charlotte, Cotogno, Patrick, Lewis, Brian, Layton, Jodi, Sartor, A. Oliver, Barata, Pedro
Publicado no Oncotarget (2020)

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

Por Armstrong, Andrew J., Eisenberger, Mario A., Halabi, Susan, Oudard, Stephane, Nanus, David M., Petrylak, Daniel P., Sartor, A. Oliver, Scher, Howard I.
Publicado em 2011

Cytokine genetic polymorphisms and prostate cancer aggressiveness

Por Zabaleta, Jovanny, Su, L. Joseph, Lin, Hui-Yi, Sierra, Rosa A., Hall, M. Craig, Sartor, A. Oliver, Clark, Peter E., Hu, Jennifer J., Ochoa, Augusto C.
Publicado em 2009

Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer: A Southwest Oncology Group Trial (SWOG 9426)

Por Sartor, A. Oliver, Tangen, Catherine M., Hussain, Maha H. A., Eisenberger, Mario A., Parab, Minoti, Fontana, Joseph A., Chapman, Robert A., Mills, Glenn M., Raghavan, Derek, Crawford, E. David
Publicado em 2008

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

Por Beer, Tomasz M, Vogelzang, Nicholas, Bartůňková, Jiřina, Miller, Kurt, Oh, William, Oudard, Stephane, Pandha, Hardev, Sartor, A Oliver, Špíšek, Radek, Toole, Timothy O, Borgstein, Niels G, Gerritsen, Winald R
Publicado no J Immunother Cancer (2015)

CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion

Por Liu, Sen, Liu, Fengli, Zhang, Bing, Yan, Peng, Rowan, Brian G., Abdel-Mageed, Asim B., Steele, Chad, Jazwinski, S. Michal, Moroz, Krzysztof, Norton, Elizabeth B., Wang, Alun, Myers, Leann, Sartor, A. Oliver, Zhang, Qiuyang
Publicado no Prostate (2020)

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Ra...

Por Terrisse, Safae, Karamouza, Eleni, Parker, Chris C., Sartor, A. Oliver, James, Nicholas D., Pirrie, Sarah, Collette, Laurence, Tombal, Bertrand F., Chahoud, Jad, Smeland, Sigbjørn, Erikstein, Bjørn, Pignon, Jean-Pierre, Fizazi, Karim, Le Teuff, Gwénaël
Publicado no JAMA Oncol (2020)

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer

Por Pomerantz, Mark M., Spisák, Sandor, Jia, Li, Cronin, Angel M., Csabai, Istvan, Ledet, Elisa, Sartor, A. Oliver, Rainville, Irene, O’Connor, Edward, Herbert, Zachary T., Szállási, Zoltan, Oh, William K., Kantoff, Philip W., Garber, Judy E., Schrag, Deborah, Kibel, Adam S., Freedman, Matthew L.
Publicado no Cancer (2017)

A Phase III trial of 2 Years of Androgen Suppression (AS) and Radiation Therapy (RT) with or without Adjuvant Chemotherapy (CT) for High-Risk Prostate Cancer: Final Results of Radi...

Por Rosenthal, Seth A., Hunt, Daniel, Sartor, A. Oliver, Pienta, Kenneth J., Gomella, Leonard, Grignon, David, Rajan, Raghu, Kerlin, Kevin J., Jones, Christopher U., Dobelbower, Michael, Shipley, William U., Zeitzer, Kenneth, Hamstra, Daniel A., Donavanik, Viroon, Rotman, Marvin, Hartford, Alan C., Michalski, Jeffrey, Seider, Michael, Kim, Harold, Kuban, Deborah A., Moughan, Jennifer, Sandler, Howard
Publicado no Int J Radiat Oncol Biol Phys (2015)

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Por Smith, Matthew R., Sweeney, Christopher J., Corn, Paul G., Rathkopf, Dana E., Smith, David C., Hussain, Maha, George, Daniel J., Higano, Celestia S., Harzstark, Andrea L., Sartor, A. Oliver, Vogelzang, Nicholas J., Gordon, Michael S., de Bono, Johann S., Haas, Naomi B., Logothetis, Christopher J., Elfiky, Aymen, Scheffold, Christian, Laird, A. Douglas, Schimmoller, Frauke, Basch, Ethan M., Scher, Howard I.
Publicado no J Clin Oncol (2014)

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Por Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.
Publicado no Cancer (2019)